Free Trial

XTL Biopharmaceuticals Q2 2023 Earnings Report

XTL Biopharmaceuticals EPS Results

Actual EPS
-$0.07
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

XTL Biopharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

XTL Biopharmaceuticals Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Remove Ads

XTL Biopharmaceuticals Earnings Headlines

This AI pick beats my 2016 Nvidia prediction
There’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech companies are all scrambling to build hundreds of new mega data centers to keep up with the demand for training and using new AI models. But that’s where the problem is. It doesn’t matter how many new data centers we build, we won’t be able to keep up with the insatiable demand… We can build thousands of them — even millions.
XTL Biopharmaceuticals Ltd (XTLB)
XTL Biopharmaceuticals Ltd XTLB
See More XTL Biopharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like XTL Biopharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on XTL Biopharmaceuticals and other key companies, straight to your email.

About XTL Biopharmaceuticals

XTL Biopharmaceuticals (NASDAQ:XTLB) engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.

View XTL Biopharmaceuticals Profile

More Earnings Resources from MarketBeat